Dr. Timo Veromaa has been appointed as Professor of Practice in Drug Development. The appointment strengthen the operations of the InFLAMES Flagship, joint effort of the University of Turku and Åbo Akademi University, funded by the Academy of Finland. The purpose of the professorship of practice in drug development is to introduce more life science business and innovation expertise to the University of Turku, increase collaboration between the University and pharmaceutical companies, and help enable commercialisation of innovations.

Timo Veromaa is an MD, PhD with a research background and an eMBA from the University of Turku. He has worked in utive and board level positions in life science and health technology companies in Finland, United States, Great Britain, Germany, Sweden, and Switzerland for over 25 years. As the CEO of the drug development company Biotie Therapies Plc., listed on the stock exchange in Finland and the U.S., Veromaa was responsible for shareholder and investor relations and for national and international public and private funding agencies.

Veromaa is currently Chairman of the Board of Herantis Pharma Plc, drug development company working on gene therapy and biologics listed on the First North Growth Market stock exchange both in Helsinki and Stockholm, as well as first Chairman of Finnish Biobanks FINBB. Veromaa has had an active role in various public sector projects of the field, developing the prerequisites for business activities in Finland and has worked in various positions of trust.

Professor of Practice Timo Veromaa will give a lecture in open webinar organised on 17 May 2021 at 3 PM. Timo Veromaa’s lecture title is Building a globally competitive precision medicine ecosystem in Turku, Finland.